Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Files to Raise $10.5M

NEW YORK (GenomeWeb) – Interpace Diagnostics today said that it plans to raise about $10.5 million in a public offering of its stock.

In a document filed with the US Securities and Exchange Commission, the firm said that it will offer up to almost 6.3 million shares of its common stock as part of the offering. It also is offering to purchasers, who would own more than 4.99 percent of Interpace's outstanding common stock after the offering, the opportunity to purchase prefunded warrants in lieu of common shares that would result in the purchaser owning more than 4.99 percent of the firm's outstanding shares.

Interpace has not priced the shares yet, but said that net proceeds from the offering are estimated at $10.5 million, based upon an assumed public offering price of $1.91 per share.

The proceeds will be used for working capital, trade, payables, general corporate purposes, and other obligations.

Maxim Group is the sales book running manager, and WestPark Capital is the co-manager on the offering. Interpace has granted the underwriters an overallotment option to purchase up to an additional 942,408 shares.

Interpace said earlier this week that it signed a laboratory services deal to provide it molecular thyroid tests to researchers at Einstein Medical Center of Philadelphia. 

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.